INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Keryx Biopharmaceuticals Inc. & Encourages ...
August 05 2016 - 12:52PM
Business Wire
Goldberg Law PC (the “Firm”) announces that a class action
lawsuit has been filed against Keryx Biopharmaceuticals Inc.
(“Keryx” or the “Company”) (Nasdaq: KERX). Investors who purchased
or otherwise acquired shares between February 25, 2016 and August
1, 2016 (the “Class Period”) are encouraged to contact the Firm
prior to the October 3, 2016 lead plaintiff
motion deadline.
If you are a Keryx shareholder who suffered at least $100,000.00
in losses during the Class Period, click here to
participate. In addition, we advise you to contact Michael
Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the
Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to
discuss your rights without cost to you. You can also reach us
through the firm’s website at http://www.Goldberglawpc.com, or by
email at info@goldberglawpc.com.
The class in this case has not yet been certified, and until
certification occurs, you are not represented by an attorney. If
you choose to take no action, you can remain an absent class
member.
According to the complaint, the Company made false and
misleading statements and/or failed to disclose: that Keryx was
experiencing production-related difficulties in converting API to
finished drug product; that the issue was resulting in decreased
production yields of finished drug product; that the Company
exhausted its reserve of finished drug product; and as a result of
the above, Keryx’s statements about its business, operations and
prospects were false and misleading and/or lacked a reasonable
basis at all relevant times.
Goldberg Law PC represents shareholders around the world and
specializes in securities class actions and shareholder rights
litigation.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160805005667/en/
Goldberg Law PC, Los AngelesMichael Goldberg, Esq.,
800-977-7401Brian Schall, Esq.,
800-977-7401info@goldberglawpc.comwww.Goldberglawpc.com
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Keryx Biopharmaceuticals, Inc. (delisted) (NASDAQ:KERX)
Historical Stock Chart
From Apr 2023 to Apr 2024